Bringing up BIIB
Biogen Idec Inc. has been on a tear of late, boosted by its updated guidance last week, ongoing acquisition rumors fueled by the Federal Trade Commission's approval of a stock purchase by activist investor Carl Icahn in late August, and its stock buyback in early July.
Last Thursday, BIIB (Cambridge, Mass.) committed to maintaining its rates of both top and bottom line growth over the next three years. At the Thomas Weisel conference in Boston, the company offered guidance that revenues